Management Team

- William 'Obi' M. Greenman - President and CEO

- Richard J. Benjamin MBChB, PhD, FRCPath - Chief Medical Officer

- Laurence M. Corash, M.D. - Chief Scientific Officer

- Kevin D. Green - VP, Finance and Chief Financial Officer

- Caspar Hogeboom - President, Cerus Europe and EEMEA

- Suzanne Margerum - VP, Manufacturing and Operations

- Chrystal Menard - Chief Legal Officer and General Counsel

- Carol Moore -  SVP, Regulatory Affairs and Quality

- Nina Mufti -  VP, Development

- Lori L. Roll - VP, Administration and Corporate Secretary

- Adonis Stassinopoulos -  VP, Global Scientific Affairs and Research

- Kenneth Trader -  VP, Sales - Americas


   William 'Obi' M. Greenman
President and CEO

Years with Cerus : 20

Mr. Greenman was named our President and Chief Executive Officer in April 2011. He had been Cerus' Chief Business Officer since April 2010. Previously, he was senior vice president, business development and marketing. From 2006 to 2008, he held the position of president, Cerus Europe, and prior to that, he served as vice president, business development. Prior to joining Cerus in 1995 as director of business development, he worked in various marketing and business development positions in Baxter's Biotech Division from 1991 to 1995.  Mr. Greenman currently is a member of the Board of Directors of Aduro Biotech. He received  his B.A.S. in Economics and Biological Sciences from Stanford University.


Richard J. Benjamin MBChB, PhD, FRCPath
Chief Medical Officer

Dr. Benjamin was appointed as Chief Medical Officer in July 2015. Previously, he served as CMO for the American Red Cross where he oversaw donor and patient safety issues for 40% of the US blood supply. Prior to Red Cross, he served as medical director at the Adult Transfusion Service at the Joint Program in Transfusion Medicine at Harvard University. Dr. Benjamin is a Board Member and Regional Director for North America for the International Society of Blood Transfusion, as well as an active member of the American Association of Blood Banks. He has also served on the DHHS Secretary’s Advisory Committee on Blood Safety and Availability in the U.S. Dr. Benjamin is an Adjunct Associate Professor of Pathology at Georgetown University and author of >100 peer-reviewed publications. He received his Ph.D. at Cambridge University, England in Immunology and completed post-doctoral research at Stanford University, CA.


Laurence M. Corash, M.D.
Chief Scientific Officer

Years with Cerus : 24

Dr. Corash, a co-founder of Cerus, was appointed as our Chief Scientific Officer in 2009. He has held various medical positions within the company, including Chief Medical Officer from 1994-2015. Dr. Corash was a consultant to us from 1991 to 1994. He has been a Professor of Laboratory Medicine at the University of California, San Francisco since July 1985 and was Chief of the Hematology Laboratory for the Medical Center at the University of California, San Francisco from 1982 to 1997. From February 1990 to July 1994, Dr. Corash was a consultant to the FDA Advisory Panel for Hematology Devices. He currently serves on the U.S. Health and Human Services' Advisory Committee on Blood Safety and Availability.


Kevin D. Green
Vice President, Finance and Chief Financial Officer

Years with Cerus : 9

Mr. Green was appointed our Chief Financial Officer in 2013. From 2006 to 2013, Mr. Green served in several roles for us including Senior Director of Finance, Controller and most recently, Vice President, Finance and Chief Accounting Officer. From 2000 until 2006, Mr. Green held various financial management positions with Macromedia, Inc., a software company acquired by Adobe Systems in 2005, including Director of Finance and Assistant Controller. Prior to joining Macromedia, Mr. Green was a member of PricewaterhouseCoopers LLP in the Assurance and Business Advisory Services division.
Mr. Green is a certified public accountant (inactive).


Caspar Hogeboom
President, Cerus Europe and EEMEA

Years with Cerus : 9

Mr. Hogeboom serves as President of Cerus Europe and EEMEA. Since joining Cerus in 2006, he has held various positions within the company including General Manager of Cerus Europe from 2011 to 2012, Managing Director of Cerus Europe from 2008 to 2011 and Managing Director, Intercept Blood Systems from 2006 to 2008. Prior to joining the Company, Mr. Hogeboom worked for Baxter Healthcare in Europe where he held several management, sales and European marketing positions from 1992 to 2006. Preceding Baxter, Mr. Hogeboom held various sales marketing positions at Maxxim Medical in the Netherlands.


Suzanne Margerum
Vice President, Manufacturing and Operations

Years with Cerus : 14

Suzanne Margerum was appointed Vice President, Manufacturing in 2005. Since joining Cerus in 2001, she has held the positions of Vice President, Development; Director of Development; and Project Leader. Her previous experience includes 13 years at The Clorox Company in technical management (product development and manufacturing) for both U.S. and international business units. Ms. Margerum holds bachelors and masters degrees in chemical engineering.


Chrystal Menard
Chief Legal Officer and General Counsel

Years with Cerus : 3

Ms. Menard was appointed Chief Legal Officer in 2012. Prior to joining Cerus, Ms. Menard served as senior corporate counsel at Zynga, Inc. From 2000-2011, she was a partner at Cooley LLP, where she had practiced corporate and securities law. Ms. Menard received her Juris Doctorate from the University of Chicago and her Bachelor of Science in finance and accounting from the University of Colorado, Boulder.


Carol Moore
Senior Vice President, Regulatory Affairs and Quality 

Years with Cerus :  7

Ms. Moore was promoted to Senior Vice President, Regulatory Affairs, Quality, and Clinical in 2013. She has been at Cerus since 2008, previously serving as Vice President, Regulatory Affairs, Quality and Clinical. Prior to joining Cerus, she served as Vice President, Worldwide Regulatory Affairs at Bayer Corporation. Ms. Moore was with Bayer for over 30 years, during which she was involved with registration and regulatory compliance of Bayer’s biological and biotech products, health policy, and strategic planning.


Nina Mufti
Vice President, Development

Years with Cerus : 8

Nina Mufti, Ph.D., was promoted to Vice President, Development at Cerus Corporation in 2012. Since 2007, she has guided the product design and development efforts for the INTERCEPT RBC System. Prior to Cerus, Dr. Mufti worked at Nektar Therapeutics on the development of drug and device combination products.  Dr. Mufti completed her Ph.D. in Biochemical Engineering at Cornell University, and her Bachelors of Science, Biochemistry and  Bachelors of Applied Science, Chemical Engineering at University of Ottawa.


Lori L. Roll
Vice President, Administration and Corporate Secretary

Years with Cerus : 23

Ms. Roll was appointed our Vice President, Administration in 1999. From 1997 to 1999 she was our Director of Administration, and from 1992 to 1997 she served as our Controller. Prior to joining Cerus, Ms. Roll spent six years working as a certified public accountant for Ernst & Young and also served as a Controller for two private companies.


Adonis Stassinopoulos
Vice President, Global Scientific Affairs and Research

Years with Cerus : 14

Dr. Stassinopoulos was appointed Vice President of Global Scientific Affairs in 2011.  Prior to rejoining Cerus he served in various positions in Chiron/Novartis V&D between 2005 to the end of 2010 including Franchise Head of Development Transfusion Medicine.  From 1996 to 2005 he served Cerus in various roles including Red Cell Development Team Leader and Director within the Transfusion Medicine Research Department.  Dr Stassinopoulos received his Bachelor of Science, Cum Laude, in Chemistry from Patras University in Greece, and Ph.D. in Bioinorganic Chemistry from Yale University and completed his Postdoctoral Fellowship at Harvard Medical School. 


Kenneth Trader
Vice President, Sales - Americas

Years with Cerus : 2

Ken Trader comes to Cerus with twenty-five years of leadership experience in sales and marketing management, having served most recently as vice president, sales and payer relations at US Bioservices, a division of AmerisourceBergen Specialty Group. Prior to this role, Mr. Trader served as vice president, corporate business development at AmerisourceBergen Specialty Group. He has also previously held the roles of vice president of sales and marketing, hemophilia health services with Accredo Health Group, and director of national sales with Baxter BioScience, a division of Baxter Healthcare Corporation. Throughout his career, Mr. Trader has consistently demonstrated success in numerous biologic product launches and in building out commercial organizations. Mr. Trader has served on the National Hemophilia Foundation's board of directors since 2010, and currently holds the position of vice chair.


  • Global Headquarters

  • 2550 Stanwell Drive
    Concord, CA US 94520
    +1 925.288.6000
  • European Headquarters

  • Stationsstraat 79-D
    3811 MH Amersfoort, Netherlands
    +31 (0) 33 49 60 600